Dr. Mónica García Gómez Minister of Health of the Government of Spain Ministry of Health Paseo del Prado, 18 28014 – Madrid
Dear Minister,
We wish to inform you that we are witnessing with considerable dismay an advertising campaign by the Israeli pharmaceutical company Teva regarding its drug fremanezumab, marketed in our country, as you know, under the name Ajovy, a medication for the prevention of migraines.
This advertising campaign began on February 25, 2016, and is still ongoing. This campaign has been carried out with the support of a large number of Spanish media outlets, both general and specialized medical (see the list of news articles at the end of this document). Scientific organizations such as the Spanish Society of Outpatient and Primary Care Pediatrics (SEPEAP) and online forums such as Ser Padres have also reported on this matter.
Regarding this propaganda campaign, the State Boycott Campaign "Teva? No, thanks," which to date has been joined by 402 organizations from all regions of Spain, wishes to state the following:
1) In our opinion, although this advertising campaign has adopted the form of an "aseptic" scientific dissemination to the public of the results of this study, avoiding in principle using the trade name of this product, its presentation makes it very easy to recognize. In fact, in some news articles, such as those published by the EFE news agency, the Diario de Sevilla newspaper, Hoy Aragón, or on the Antena 3 website, the text is accompanied by a photo of an "Ajovy" injection (See list of news articles at the end).
2) We will not assess the scientific and technical quality of this study, conducted with 234 patients between 6 and 17 years old, of whom 123 received treatment for 3 months and the remaining 111 received a placebo. We do, however, question whether the results obtained justify such a campaign of propaganda and the excessive generation of expectations among the general population and among patients who suffer from migraines and their parents. In our opinion, this is not the case, and therefore we believe that misleading advertising is being used.
3) It should be noted that this clinical trial is funded by Teva Pharmaceuticals itself (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT04458857). Of the 11 authors who signed the article, no fewer than 10 declare potential conflicts of interest due to their relationship with Teva. The only one who does not declare any is the article's first author, Dr. Andrew Hershey. Given this situation, it seems prudent to distance oneself from the results obtained, and it is somewhat scandalous that this publication was included in the prestigious New England Journal of Medicine.
4) A particularly important case is that of the Spanish representative in this trial, Dr. Patricia Pozo Rosich, as she is repeatedly cited and "interviewed" in the various texts that make up the promotional campaign.
Patricia Pozo Rosich is a neurologist specializing in migraines. Since July 2025, she has been Head of the Neurology Department at Vall d'Hebron University Hospital in Barcelona. She leads the headache research group at the VHIR (Vall d'Hebron Research Institute) and is a person of considerable public presence and impact.
She is also the main KOL (Key Opinion Leader) for the Teva laboratory in Spain, from which she received "transfers of value" totaling €44,652 in 2024. In 2023, the figure was €31,654. Furthermore, she has a very serious conflict of interest. In reality, it is the management of the Vall d'Hebron Research Institute that has the conflict.
The Internal Scientific Committee of this institution lists Dr. Patricia Pozo Rosich as Vice President… and on its External Scientific Committee is Professor Ronit Satchi-Fainaro, an Israeli pharmacist and member of the Board of Directors of Teva, a fact which is conveniently omitted from her brief curriculum vitae description on the website.
With this structure, it is difficult to give much credence to anything Dr. Pozo Rosich says in defense of fremanezumab.
5) To our understanding the direct objective of the propaganda campaign is to pave the way for demanding an expansion of the indications to include the pediatric and adolescent population with migraine, an attempt to increase the market share of this product, disguising it as "science" and genuine concern for the health of such a vulnerable segment as children.
As you are well aware, in Spain Ajovy is currently indicated for the prophylaxis of migraine in adults with at least four migraine days per month. It is covered by the National Health System for patients with 8 or more migraine days per month (high-frequency episodic migraine and chronic migraine) and 3 or more failed previous treatments at sufficient doses for at least 3 months, one of which was botulinum toxin in the case of chronic migraine.
It is a hospital diagnostic (HD) and hospital-dispensed drug without a tamper-evident coupon (HDSC), meaning it must be prescribed by neurology specialists and dispensed, free of charge to the patient, in hospital pharmacy departments. It is administered subcutaneously, in a 225 mg dose (monthly), as an injectable solution in a pre-filled syringe, at a price of €498 in the Spanish National Health System (a price that can be reduced by more than 50% in specific offers, such as those Teva uses to negotiate a favorable market position). In the United States, the price is $746. A 675 mg dose is available for quarterly administration.
There are three other similar antibodies authorized in the Spanish pharmaceutical market. The Spanish Agency for Medicines and Health Products (AEMPS), in its 2020 Therapeutic Positioning Report on Ajovy, stated the following: “There is a lack of direct comparative data with other prophylactic alternatives, such as topiramate, botulinum toxin, beta-blockers, flunarizine, or amitriptyline, or even other drugs with the same mechanism of action (erenumab, galcanezumab). The limited evidence available shows a modest clinical benefit and does not allow us to consider it superior to other available options for migraine prophylaxis.”
For its part, the Navarre Pharmacotherapeutic Information Bulletin (2021) concluded the following: “Having demonstrated their efficacy and safety in migraine prevention compared to placebo, their efficacy remains modest, there are no comparative studies against standard therapies, and data on long-term effectiveness and safety in real-world clinical practice are scarce. Furthermore, the incorporation of ACs into migraine treatment carries a significant economic impact, motivated not only by their cost, which is around €150-200 per month per patient (€1800-2300 per year per patient), but also by the high prevalence of the disease and its chronic nature.
Therefore, it is necessary to position ACs in relation to other preventive treatments and develop guidelines for action that guide local clinical practice and include the approval and funding requirements of each country.”
6) We believe that this advertising campaign violates the provisions of Article Article 78 of Law 29/2006, of July 26, on guarantees and rational use of medicines and medical devices.
It is covertly advertising a marketed medicine—albeit in a different presentation or with a different indication—and financed by the National Health System (Art. 78.6).
It is also a medicine intended to be used or applied exclusively by healthcare professionals (Art. 78.7). The advertising includes "testimonials about the virtues of the product (...) from professionals or individuals whose notoriety may induce consumption," as is the case of the aforementioned Dr. Pozo Rosich (Art. 78.2.d).
Furthermore, the ultimate target audience of this advertising is minors, who are specially protected by Article 3.b of Law 34/1988, of November 11, the General Advertising Law.
7) Finally, we want to point out the close ties between the pharmaceutical company Teva and the Zionist government of Israel, its armed forces (IDF), and the ongoing genocide in Gaza. Teva is lying when it denies these ties.
We have clearly explained this in Report 5 of the "Teva Reports" series, entitled "The Darkness of Teva," available on our website (www.tevanogracias.com), which we have also attached as an enclosed file. Teva is the largest company by market capitalization on the Tel Aviv Stock Exchange.
Therefore, it is not just any company, nor simply a company concerned only with its business, as they claim. Teva is, above all, a key component of the Zionist financial network that sustains the occupation of the land of Palestine and the plan of ethnic cleansing and extermination of its population. Therefore, there are powerful ethical and deontological arguments for boycotting it and limiting its use.
We demand that Teva cease all possible activity in Spain. To do otherwise is to collaborate with someone who supports the most atrocious barbarity.
The vast majority of their medications can be perfectly substituted by other brands without any impact on people's health, as is even the case with fremanezumab.
Teva's argument of alleged harm to public health if their medications lose market share is another fallacious argument.
Therefore, we REQUEST:
1/ The opening of an investigation to clarify whether the Teva company and the media outlets that have participated in this propaganda campaign have committed any legal or administrative infraction. If so, we request that the corresponding sanctions be applied. And
2/ That, in compliance with the recommendations of the International Court of Justice and the United Nations, the Ministry implement legal, administrative, economic, and political measures to limit the activities of this pharmaceutical company in our country due to its proven ties to the State of Israel and its policies of extermination of the Palestinian people.
Thank you for listening.
Sincerely, State Boycott Campaign "Teva? No, thanks."
Contact: tevanogracias@proton.me
LIST OF NEWS ITEMS DETECTED AS PART OF TEVA'S ADVERTISING CAMPAIGN
This is an incomplete list, as it is impossible to compile all the news items, since this information has been widely disseminated in all types of forums and media. Many of these news items reproduce almost verbatim the news published by the EFE Agency in Catalonia or are based on it. This EFE news report already includes a photo of the Ajovy injection.
-EFE News Agency (Catalonia) https://efe.com/cataluna/2026-02-25/demuestran-la-eficacia-de-un-farmaco-para-tratar-la-migrana-en- la-poblacion-pediatrica/
-Spanish Society of Outpatient Pediatrics and Primary Care (SEPEAP) https://sepeap.org/fremanezumab-en-ninos-y-adolescentes-con-migrana-episodica/
-The La Vanguardia https://www.google.com/amp/s/www.lavanguardia.com/vida/20260225/11473658/primer-tratamiento- preventivo-migrana-ninos-adolescentes.amp.html
-TV3 https://www.3cat.cat/3catinfo/un-estudi-obre-la-porta-al-primer-tractament-eficac-contra-la-migranya- en-infants-i-adolescents/noticia/3396463/ Diario de Sevilla https://www.diariodesevilla.es/salud/fremanezumab-medicamento-migrana-pediatrica-llegara-espana- 2026_0_2006012510.html
-El Periódido https://www.google.com/amp/s/amp.elperiodico.com/es/sanidad/20260225/primer-farmaco-migrana- pediatrica-fremanezumab-inyeccion-espana-vall-hebron-127081489
-Diario Farma https://diariofarma.com/2026/02/25/un-estudio-avala-fremanezumab-para-reducir-los-dias-de-migrana- en-ninos-y-jovenes
-IM Medico https://www.google.com/amp/s/www.immedicohospitalario.es/amp/55316/nuevo-tratamiento-con- fremanezumab-demuestra-eficacia-y-seguridad-en-l.html
-The Huffington Post https://www.google.com/amp/s/www.huffingtonpost.es/life/salud/patricia-pozorosich-neurologa- sobrefremanezumab-para-migrana-infantil-habia-ningun-tratamiento-preventivo-aprobado- f202602.html%3foutputType=amp
-El Mundo https://www.google.com/amp/s/amp.elmundo.es/ciencia-y- salud/salud/2026/02/25/699ed17d21efa043168b4575.html
-Faro de Vigo https://www.farodevigo.es/sociedad/2026/02/26/espana-tendra-ano-primer-farmaco-127290644.html
-Hoy Aragon https://www.hoyaragon.es/articulo/noticias-espana/llega-espana-fremanezumab-primer-farmaco- migrana-pediatrica-inyeccion-fin/20260301134316124076.html
-El Economista https://www.google.com/amp/s/www.eleconomista.es/salud-bienestar/ultimas- noticias/amp/13796750/espana-consigue-el-primer-farmaco-contra-las-migranas-para-ninos-asi-es-el- fremanezumab-que-se-administra-con-una-inyeccion-al-mes
-20 minutos https://www.20minutos.es/salud/fremanezumab-primer-tratamiento-contra-migranas- ninos_6939511_0.html
-Heraldo https://www.google.com/amp/s/www.heraldo.es/noticias/salud/2026/02/26/adios-migrana-descubren- medicamento-fremanezumab-eficaz-ninos-adolescentes-1897530.amp.html
-La Razón https://www.google.com/amp/s/www.larazon.es/sociedad/primer-tratamiento-preventivo-migrana- pediatrica-llegara-espana-inyeccion-mensual- b50m_2026022769a163d59243cc133c668cfd.html%3foutputType=amp Antena 3 https://www.google.com/amp/s/amp.antena3.com/noticias/salud/primer-tratamiento-migrana-ninos- adolescentes-sido-milagro-hija_20260225699f08352f00a0468827a619.html
-Tele 5 https://www.telecinco.es/noticias/salud/20260225/farmaco-reduce-primera-vez-preventiva-migrana- ninos-adolescentes-
-El Periódico - Extremadura https://www.elperiodicoextremadura.com/sociedad/2026/03/07/espana-tendra-ano-fremanezumab- primer-dv-127683422.html
